Wren

Cariprazine

Cariprazine is a prescription medicine well established for treating adult bipolar I lows and settling mania, the more severe high.

Restlessness and movement changes are important daily difficulties. The medicine stays active in the body for weeks, so benefit and side effects need time to be judged after a change. Its US brand Vraylar is licensed for bipolar treatment; UK Reagila is licensed for schizophrenia, with bipolar use outside that licence.⁠

Cariprazine is an antipsychotic, a group of medicines used for losing touch with reality, such as hearing voices or holding beliefs that are not true, and also for mood episodes. Bipolar I includes a history of mania. Schizophrenia is a different condition that can include persistent difficulties with perception, beliefs and thinking.⁠

What it helps with

Cariprazine is well established for adult bipolar I depression and mania. The Canadian and international guideline places it among the first choices for both phases. The US product also covers a high with low symptoms at the same time, often called a mixed state. For a low, benefit is assessed over several weeks; the trials mainly judged improvement by about six weeks.⁠

Keeping future episodes away needs its own treatment discussion. The guideline's established prevention choices include lithium, quetiapine and several other medicines, with the person's previous response and daily effects shaping the plan.⁠

In the UK, prescribing Reagila for bipolar is off-label, meaning a clinician uses a medicine for a purpose outside its product licence. That use rests on the bipolar evidence and an individual prescribing decision. The conversation can cover why it is being chosen, access to prescriptions and who will follow up benefit and side effects.⁠

Taking it day to day

Cariprazine is taken once a day, at the same time, with or without food. The prescriber, the clinician who writes the prescription, adjusts the amount according to response and the product being supplied.⁠

For Reagila, a missed dose is taken when remembered unless the next dose is almost due. Then it is skipped and the next taken at the usual time. Two doses are never taken to catch up. A pharmacist can clarify timing for the particular prescription.⁠

Cariprazine and the active substances the body makes from it build up and leave slowly. A change in dose can take several weeks to show its full effect, and side effects can appear after treatment has seemed manageable at first. Keeping a few dated notes about sleep, restlessness and daily tasks makes later changes easier to recognise. Follow-up continues over several weeks after starting or changing the dose.⁠

Side effects and ways to manage them

Restlessness and movement

Cariprazine can cause an uncomfortable inner restlessness with a compelling need to keep moving. Clinicians call this akathisia. Pacing, rocking or repeatedly moving the legs can make sitting through a meal or settling for sleep hard. It deserves a prompt medicine review, particularly when it begins after treatment starts or changes. The prescriber can adjust treatment to reduce it.⁠

Shaking, stiffness, slowed movement or an unusual way of walking can also be medicine effects. New uncontrollable movements of the face, tongue or limbs need prompt medical advice. Bringing the dates of medicine changes and describing what is difficult helps review these symptoms alongside mood.⁠

Sleep, stomach symptoms and physical checks

Sleepiness, dizziness, nausea or difficulty sleeping can affect ordinary life. Driving, cycling and machinery need to wait while alertness or balance is affected. Standing slowly and sitting down when dizzy reduce the chance of falling. If a change keeps getting in the way, a medicine discussion can weigh the benefit already gained against the daily burden.⁠

Weight, blood pressure, blood sugar and fats in the blood need checks around starting and afterwards. Weight or blood changes can occur without obvious symptoms. The guideline recommends weight monthly for the first three months, then every three months, with blood pressure, sugar and fats at three months and yearly afterwards. Regular meals and activity fitted to mood and energy give a manageable routine while changes are reviewed.⁠

Other medicines and alcohol

Other medicines can change how quickly the body breaks down cariprazine, raising side effects or reducing benefit. Reagila's instructions rule out combinations with carbamazepine, St John's wort, a herbal remedy sometimes taken for low mood, and certain antibiotics or antifungals. The pharmacist needs the full list when something is started or stopped. The effects of an interaction can also take weeks to settle.⁠

Grapefruit juice is avoided because it can raise medicine levels. Reagila's information advises avoiding alcohol. Alcohol or cannabis alongside treatment covers the wider questions about sleep and mood.⁠

Stopping and pregnancy planning

A stop or switch needs the prescriber's plan because active medicine remains in the body for weeks. The plan takes account of overlap with another medicine, returning symptoms and delayed side effects; follow-up continues after the final dose.⁠

Pregnancy evidence is limited, and Reagila's product information advises avoiding pregnancy during treatment. It specifies effective contraception during treatment and for at least ten weeks after the last dose because the medicine leaves the body slowly. It also advises against breastfeeding during treatment. Pregnancy planning and feeding decisions can weigh another treatment alongside the importance of keeping the parent well.⁠

Problems needing urgent help

A high temperature with severe stiffness, sweating and confusion needs emergency medical assessment. Sudden swelling of the mouth or throat, difficulty breathing, a seizure or collapse also needs emergency help; in England this means 999 or an emergency department. Taking more than prescribed needs urgent medical advice even when symptoms have yet to appear, because effects can be delayed.⁠

Related: Medicines for bipolar · A medicine discussion · What helps when low.

Sources

  1. 1The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence Guideline
  2. 2VRAYLAR® (cariprazine) capsules, for oral use US product information
  3. 3Reagila 1.5 mg hard capsules UK medicines guide
  4. 4Bipolar disorder: assessment and management NICE

Last updated 12 October 2026